These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29628176)

  • 1. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
    Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
    Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
    Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
    Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].
    Nicola F; García Ramírez D; Arduino S; Di Chiara M; Smayevsky J
    Rev Argent Microbiol; 2010; 42(3):193-8. PubMed ID: 21186673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
    Gimeno C; Cantón R; García A; Gobernado M;
    Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem-Nonsusceptible
    Asempa TE; Nicolau DP; Kuti JL
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31118271
    [No Abstract]   [Full Text] [Related]  

  • 16. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
    Bretonnière C; Maitte A; Caillon J; Potel G; Boutoille D; Jacqueline C; Guitton C
    J Antibiot (Tokyo); 2016 Nov; 69(11):806-810. PubMed ID: 27025352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
    van der Bij AK; Mol M; van Westreenen M; Goessens WH; Pitout JD
    Scand J Infect Dis; 2011 Aug; 43(8):596-602. PubMed ID: 21506891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.